for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Charles River Laboratories Intl. Inc

CRL

Latest Trade

138.07USD

Change

-0.57(-0.41%)

Volume

45,907

Today's Range

137.73

 - 

138.46

52 Week Range

103.00

 - 

149.07

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
138.64
Open
137.82
Volume
45,907
3M AVG Volume
6.89
Today's High
138.46
Today's Low
137.73
52 Week High
149.07
52 Week Low
103.00
Shares Out (MIL)
48.81
Market Cap (MIL)
6,766.63
Forward P/E
21.24
Dividend (Yield %)
--

Next Event

Q3 2019 Charles River Laboratories International Inc Earnings Release

Latest Developments

More

Charles River Laboratories Reports Q2 EPS Of $0.88

Charles River Laboratories Invests In Resero Analytics

Charles River Laboratories Q1 GAAP Earnings Per Share $1.11

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Charles River Laboratories Intl. Inc

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Industry

Biotechnology & Drugs

Contact Info

251 Ballardvale St

+1.781.2226000

http://www.criver.com

Executive Leadership

James C. Foster

Chairman of the Board, President, Chief Executive Officer

David Ross Smith

Chief Financial Officer, Corporate Executive Vice President

David P. Johst

Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel

William D. Barbo

Corporate Executive Vice President and Chief Commercial Officer

Birgit Girshick

Corporate Executive Vice President, Discovery and Safety Assessment, Biologics and Avian

Key Stats

2.07 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.7K

2017

1.9K

2018

2.3K

2019(E)

2.6K
EPS (USD)

2016

4.560

2017

5.270

2018

6.030

2019(E)

6.526
Price To Earnings (TTM)
32.01
Price To Sales (TTM)
2.76
Price To Book (MRQ)
4.65
Price To Cash Flow (TTM)
17.12
Total Debt To Equity (MRQ)
142.56
LT Debt To Equity (MRQ)
140.23
Return on Investment (TTM)
5.91
Return on Equity (TTM)
5.08

Latest News

FOCUS-Blue-blooded crabs at heart of pharma dispute on drug testing

If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs.

BRIEF-Charles River Laboratories Q4 GAAP Loss Per Share $0.63

Charles River Laboratories International Inc:

BRIEF-Charles River Laboratories reports Q3 non-GAAP EPS of $1.30

Charles River Laboratories International Inc:

BRIEF-Charles River Laboratories posts Q2 adj. earnings $1.29/shr

Charles River Laboratories International Inc

BRIEF-Charles River Laboratories acquires Brains On-Line

Charles River Laboratories International Inc

BRIEF-Spago Nanomedical signs deal with Charles River Laboratories for preclinical studies

* ANNOUNCE AGREEMENT WOTH CHARLES RIVER LABORATORIES FOR PRECLINICAL STUDIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up